These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34244996)

  • 1. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
    Boyle EM; Rosenthal A; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Davies FE; Walker BA; van Rhee F; Morgan GJ
    Br J Haematol; 2021 Oct; 195(2):283-286. PubMed ID: 34244996
    [No Abstract]   [Full Text] [Related]  

  • 2. CD138
    Shuai W; Li S
    Blood; 2019 Sep; 134(11):906. PubMed ID: 31515228
    [No Abstract]   [Full Text] [Related]  

  • 3. BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis.
    Bai H; Chen B
    Cancer Gene Ther; 2020 Feb; 27(1-2):108-111. PubMed ID: 31801989
    [No Abstract]   [Full Text] [Related]  

  • 4. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.
    Manasanch EE; Berrios D; Fountain E; Claussen CM; Chuang T; Kaufman G; Amini B; Bashir Q; Nieto Y; Qazilbash M; Patel K; Thomas SK; Weber DM; Berkova Z; Toruner G; Lin P; Feng L; Lee HC; Orlowski RZ; Kunacheewa C
    Br J Haematol; 2021 Feb; 192(4):e115-e120. PubMed ID: 33486754
    [No Abstract]   [Full Text] [Related]  

  • 5. Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.
    van Laar R; Flinchum R; Brown N; Ramsey J; Riccitelli S; Heuck C; Barlogie B; Shaughnessy JD
    BMC Med Genomics; 2014 May; 7():25. PubMed ID: 24885236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1α.
    Wang M; Zhao HY; Zhang JL; Wan DM; Li YM; Jiang ZX
    Exp Cell Res; 2020 Nov; 396(1):112280. PubMed ID: 32961145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.
    Mithraprabhu S; Reynolds J; Turner R; Quach H; Horvath N; Kerridge I; Kalff A; Bergin K; Hocking J; Yuen F; Khong T; Durie BM; Spencer A
    Blood Cancer J; 2023 Feb; 13(1):25. PubMed ID: 36781844
    [No Abstract]   [Full Text] [Related]  

  • 8. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.
    Colla S; Storti P; Donofrio G; Todoerti K; Bolzoni M; Lazzaretti M; Abeltino M; Ippolito L; Neri A; Ribatti D; Rizzoli V; Martella E; Giuliani N
    Leukemia; 2010 Nov; 24(11):1967-70. PubMed ID: 20811474
    [No Abstract]   [Full Text] [Related]  

  • 9. Anaplastic variant of plasma cell myeloma with Dutcher bodies.
    Chang H; Kajal B
    Blood; 2016 Jun; 127(25):3291. PubMed ID: 28092870
    [No Abstract]   [Full Text] [Related]  

  • 10. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.
    Heuck CJ; Mehta J; Bhagat T; Gundabolu K; Yu Y; Khan S; Chrysofakis G; Schinke C; Tariman J; Vickrey E; Pulliam N; Nischal S; Zhou L; Bhattacharyya S; Meagher R; Hu C; Maqbool S; Suzuki M; Parekh S; Reu F; Steidl U; Greally J; Verma A; Singhal SB
    J Immunol; 2013 Mar; 190(6):2966-75. PubMed ID: 23408834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
    Nair B; Shaughnessy JD; Zhou Y; Astrid-Cartron M; Qu P; van Rhee F; Anaissie E; Alsayed Y; Waheed S; Hollmig K; Szymonifka J; Petty N; Hoering A; Barlogie B
    Blood; 2009 Jun; 113(26):6572-5. PubMed ID: 19389881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
    Broyl A; Hose D; Lokhorst H; de Knegt Y; Peeters J; Jauch A; Bertsch U; Buijs A; Stevens-Kroef M; Beverloo HB; Vellenga E; Zweegman S; Kersten MJ; van der Holt B; el Jarari L; Mulligan G; Goldschmidt H; van Duin M; Sonneveld P
    Blood; 2010 Oct; 116(14):2543-53. PubMed ID: 20574050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.
    Xu D; Hu J; Xu S; De Bruyne E; Menu E; Van Camp B; Vanderkerken K; Van Valckenborgh E
    Leukemia; 2012 Jun; 26(6):1402-5. PubMed ID: 22094583
    [No Abstract]   [Full Text] [Related]  

  • 18. Disturbed MAPK pathway in early bilateral testicular extramedullary relapse of multiple myeloma.
    Huang HF; Xu J; Xu AS; Wan XY; Chen L; Fan FJ; Zhang B; Tang L; Chen WX; Sun X; Ai LS; Hou J; Sun CY; Hu Y
    Leuk Res; 2020 Aug; 95():106403. PubMed ID: 32569928
    [No Abstract]   [Full Text] [Related]  

  • 19. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
    Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
    J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
    Tacchetti P; Terragna C; Galli M; Zamagni E; Petrucci MT; Pezzi A; Montefusco V; Martello M; Tosi P; Baldini L; Peccatori J; Ruggieri M; Pantani L; Lazzaro A; Elice F; Rocchi S; Gozzetti A; Cavaletti G; Palumbo A; Cavo M
    Am J Hematol; 2014 Dec; 89(12):1085-91. PubMed ID: 25159313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.